Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors

被引：11

作者：

Sobecki-Rausch, Janelle ^{[1
]}

Barroilhet, Lisa ^{[1
]}

机构：

[1] Univ Wisconsin, Sch Med & Publ Hlth, Div Gynecol Oncol, 600 Highland Ave, Madison, WI 53792 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2019年 / 20卷 / 11期

关键词：

Anti-PD-1; treatment; Endometrial cancer; Microsatellite instability; Mismatch repair deficiency; Pembrolizumab; IMMUNE CHECKPOINT INHIBITORS; LYNCH SYNDROME; OPEN-LABEL; PEMBROLIZUMAB; SAFETY;

D O I：

10.1007/s11864-019-0679-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Among gynecologic malignancies, mismatch repair-deficient endometrial cancers show the greatest response to anti-programmed cell death-1 (PD-1) antibodies, such as pembrolizumab. Routine immunohistochemical (IHC) and molecular testing should be performed on all endometrial cancers at the time of diagnosis in order to identify endometrial cancers with mismatch repair deficiency that may show improved response to anti-PD-1 therapy in the progressive or metastatic setting. Institutional effort to enroll patients in clinical trials investigating the use of immune checkpoint inhibitors in endometrial cancer should be prioritized.

引用

页数：10

共 35 条

[1] ADAMS S, 2017, AM SOC CLIN ONCOL
[2] Balar A, 2016, EUR SOC MED ONCOL
[3] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
[4] Boland C. R, 1998, NAT CANC I WORKSH MI
[5] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, Julie R.
Lacchetti, Christina
Schneider, Bryan J.
Atkins, Michael B.
Brassil, Kelly J.
Caterino, Jeffrey M.
Chau, Ian
Ernstoff, Marc S.
Gardner, Jennifer M.
Ginex, Pamela
Hallmeyer, Sigrun
Chakrabarty, Jennifer Holter
Leighl, Natasha B.
Mammen, Jennifer S.
McDermott, David F.
Naing, Aung
Nastoupil, Loretta J.
Phillips, Tanyanika
Porter, Laura D.
Puzanov, Igor
Reichner, Cristina A.
Santomasso, Bianca D.
Seigel, Carole
Spira, Alexander
Suarez-Almazor, Maria E.
Wang, Yinghong
Weber, Jeffrey S.
Wolchok, Jedd D.
Thompson, John A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
[6] Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Chang, Liisa
Chang, Minna
Chang, Hanna M.
Chang, Fuju
[J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (02) : E15 - E21
[7] Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, Jonathan C.
Lin, Ming-Tseh
Le, Dung T.
Eshleman, James R.
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (04) : 813 - 820
[8] Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Frenel, Jean-Sebastien
Le Tourneau, Christophe
O'Neil, Bert
Ott, Patrick A.
Piha-Paul, Sarina A.
Gomez-Roca, Carlos
van Brummelen, Emilie M. J.
Rugo, Hope S.
Thomas, Shari
Saraf, Sanatan
Rangwala, Reshma
Varga, Andrea
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4035 - +
[9] Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Friedman, Claire F.
Proverbs-Singh, Tracy A.
Postow, Michael A.
[J]. JAMA ONCOLOGY, 2016, 2 (10) : 1346 - 1353
[10] Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research
Gadducci, Angiolo
Guerrieri, Maria Elena
[J]. ANTICANCER RESEARCH, 2017, 37 (11) : 5955 - 5965

← 1 2 3 4 →